产品
编 号：F761760
分子式：C19H13ClN2O2S
分子量：368.84
分子式：C19H13ClN2O2S
分子量：368.84
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 950348-60-4
产品详情
生物活性：
SLC26A3-IN-2 is an orally active inhibitor of anion exchanger protein SLC26A3 (IC50=360 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea.
体内研究：
SLC26A3-IN-2 (10 mg/kg；口服) 在 Loperamide (HY-B0418A) 诱导的小鼠便秘模型中显著增加粪便重量和颗粒数量，证明其增加小鼠粪便水化的功效。
体外研究：
SLC26A3-IN-2 (化合物3a) (10 μM; 10 min) 对 SLC26A3 的抑制率为 92%。
SLC26A3-IN-2 is an orally active inhibitor of anion exchanger protein SLC26A3 (IC50=360 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea.
体内研究：
SLC26A3-IN-2 (10 mg/kg；口服) 在 Loperamide (HY-B0418A) 诱导的小鼠便秘模型中显著增加粪便重量和颗粒数量，证明其增加小鼠粪便水化的功效。
体外研究：
SLC26A3-IN-2 (化合物3a) (10 μM; 10 min) 对 SLC26A3 的抑制率为 92%。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备